William T. Roberts - 29 Mar 2023 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Reporting relationship: Chief Accounting Officer
Issuer ticker: RYTM
Reported as of: 29 Mar 2023
Net transaction value: -$15,960
SEC form: 4
Accepted by SEC: 31 Mar 2023, 21:38:20 UTC
Prior SEC filing: 14 Feb 2023
Source filing: View source filing
Reporting owner signature: /s/ Hunter Smith, Attorney-in-Fact for William T. Roberts

Key filing fact

William T. Roberts filed Form 4 for RHYTHM PHARMACEUTICALS, INC. (RYTM) on 31 Mar 2023.

Key facts

This page summarizes William T. Roberts's Form 4 filing for RHYTHM PHARMACEUTICALS, INC. (RYTM).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 31 Mar 2023, 21:38.

Change

Previous filing in this sequence was filed on 14 Feb 2023.
Current net transaction value: -$15,960.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RYTM transaction

Common Stock

Options Exercise

Transaction value
Shares: +2,500
Change %: +40%
Price
Shares after: 8,784
Date: 29 Mar 2023
Ownership: Direct
Footnotes: F1

RYTM transaction

Common Stock

Sale

Transaction value: $15,960
Shares: -912
Change %: -10%
Price: $17.50
Shares after: 7,872
Date: 29 Mar 2023
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RYTM transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value: $0
Shares: -2,500
Change %: -33%
Price: $0.000000
Shares after: 5,000
Date: 29 Mar 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500
Exercise price
Footnotes: F1, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

Footnote F2

The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 instruction solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.

Footnote F3

The restricted stock units vest or have vested as to 50% of the shares on each of March 29, 2024 and March 29, 2025. The restricted stock units have no expiration date.